Braveheart Bio is a late clinical-stage biotechnology company focused on treating hypertrophic cardiomyopathy and related cardiac conditions. Its lead candidate, BHB-1893, is a small-molecule, selective cardiac myosin inhibitor designed to reduce over-contraction of the heart muscle and improve cardiac filling and pumping efficiency in HCM patients. HCM is one of the most common rare diseases, affecting roughly 1 in 500 people in the United States, underscoring the sizable medical need Braveheart aims to address. The company is led by President and CEO Dr. Travis Murdoch and operates out of San Francisco, California. In November 2025, Braveheart secured $185 million in Series A financing, providing substantial capital to advance late-stage clinical trials and broaden its research pipeline. The newly raised funds will be deployed to expand operations and intensify R&D efforts around BHB-1893 and potential follow-on programs. Although revenue and user metrics are not yet relevant at this clinical stage, the large Series A round positions the company to progress toward pivotal studies and eventual regulatory submissions.

Total raised

$185M

Funding rounds

1

Latest round

Series A

Latest activity

Nov 2025